Triplet Therapeutics
Brian joined Triplet Therapeutics, Inc. in 2018 and serves as Senior Vice President, Research. Brian has held various leadership roles in bioinformatics and biostatistics, including most recently leading the Bioinformatics group at Translate Bio. He led the development of siRNA efficacy prediction in Bioinformatics and founded the Biometrics department at Alnylam Pharmaceuticals. Prior to moving to industry, Brian was a professor in Biology at the University of Massachusetts Lowell with a research focus on Drosophila models of triplet expansion.
This person is not in any offices
Triplet Therapeutics
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.